Neuroimmune modulation through vagus nerve stimulation reduces inflammatory activity in Crohn's disease patients: a prospective open label study.
Geert D'HaensMichael EberhardsonZeljko CabrijanSilvio DaneseRemco van den BergMark LöwenbergGionata FiorinoP Richard SchuurmanGöran LindPer AlmqvistPeder S OlofssonKevin J TraceyStephen B HanauerRalph ZitnikDavid ChernoffYaakov A LevinePublished in: Journal of Crohn's & colitis (2023)
Neuroimmune modulation via vagus nerve stimulation was generally safe and well-tolerated with a clinically meaningful reduction in clinical disease activity associated with endoscopic improvement, reduced levels of faecal calprotectin and serum cytokines, and improved quality-of-life.
Keyphrases
- disease activity
- systemic lupus erythematosus
- rheumatoid arthritis
- open label
- end stage renal disease
- rheumatoid arthritis patients
- ankylosing spondylitis
- ejection fraction
- newly diagnosed
- chronic kidney disease
- juvenile idiopathic arthritis
- clinical trial
- peritoneal dialysis
- oxidative stress
- prognostic factors
- ultrasound guided
- squamous cell carcinoma
- randomized controlled trial
- radiation therapy
- study protocol
- rectal cancer
- placebo controlled